French biotechnology company MedDay has acquired the health division of Profilomic to bolster its current metabolomics research platform SPECMET.
Financial details of the transaction have not been disclosed.
Go deeper with GlobalData
Under the acquisition, MedDay has purchased Profilomic's complete health-related assets, including an extensive database and laboratory equipment, in addition to a team of scientists in the field of metabolomics and lipidomics.
MedDay chief executive officer Frédéric Sedel said: “With the acquisition of Profilomic, we have significantly expanded our research capabilities and are excited to expand our pipeline.
"We fully intend to identify more opportunities to expand further and will continue to invest in our pipeline through future corporate developments.”
"MedDay is moving towards its goal of building a fully integrated biotechnology company, operating from discovery through to commercialisation.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIt is expected that the move will enable MedDay to expand its neurological disorder therapies, as well as strengthen the existing partnership with Commissariat à l’Energie Atomique (CEA).
Developed in partnership with the CEA, the SPECMET platform focuses on identifying new therapeutic targets through metabolomics analysis of cerebrospinal fluid (CSF).
It involves the screening of CSF in patients with various central nervous system (CNS) disorders to detect the disrupted metabolic pathways.
The platform then identifies and develops the compounds that affect these metabolic pathways.
Such compounds can progress into preclinical studies and clinical development based on the metabolic signatures identified in certain neurological conditions.
